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11b-Hydroxysteroid dehydrogenase type 1 expression in 2S FAZA hepatoma
cells is hormonally regulated : a model system for the study of hepatic
glucocorticoid metabolism
Michael W. VOICE, Jonathan R. SECKL, Christopher R. W. EDWARDS and Karen E. CHAPMAN*
Department of Medicine, Western General Hospital, University of Edinburgh, Edinburgh EH4 2XU, U.K.
11b-Hydroxysteroid dehydrogenase (11b-HSD) is a key enzyme
in glucocorticoid metabolism, catalysing the conversion of active
glucocorticoids into their inactive 11-keto metabolites, thus
regulating glucocorticoid access to intracellular receptors. The
type 1 isoform (11b-HSD 1) (EC 1.1.1.146) is widely distributed,
with particularly high levels in liver, where accumulating evidence
suggests that it acts as an 11b-reductase, regenerating active
glucocorticoids. Investigation of the function and regulation of
11b-HSD 1 in liver has been hampered by the lack of hepatic cell
lines which express 11b-HSD 1. Here, we describe 11b-HSD 1
mRNA expression and activity in 2S FAZA cells, a continuously
INTRODUCTION
11b-Hydroxysteroid dehydrogenase (11b-HSD) plays a key role
in glucocorticoid metabolism, catalysing the oxidation of gluco-
corticoids [cortisol (F) in humans, corticosterone (B) in rats] to
their physiologically inert 11-keto metabolites [cortisone (E) in
humans, 11-dehydrocorticosterone (A) in rats] [1,2]. At least two
isoforms of 11b-HSD exist [3–5]. 11b-HSD type 1 (11bHSD 1) is
widely distributed with high levels of expression in liver and
proximal renal tubules and lower levels elsewhere [6]. In contrast,
11b-HSD type 2 is largely restricted to aldosterone target tissues
and the placenta [7,8]. 11b-HSD 2, the encoding cDNA of which
has recently been cloned [7,9,10], is exclusively a dehydrogenase
(glucocorticoid-inactivating) both in itro and in io, and is
NAD-dependent with a high affinity for its steroid substrates
[4,5,7]. It has a well-characterized role in the distal nephron
where it confers aldosterone selectivity on renalmineralocorticoid
receptors [8,11], and in the placenta where it acts as a barrier to
maternal glucocorticoids [12,13].
11b-HSD 1, a lower-affinity NADP(H)-dependent enzyme,
has been purified from rat liver [14] and the corresponding
cDNA and gene have been cloned [15,16]. Homologues have
been isolated from a variety of species [6,17–19]. The highest
levels of 11b-HSD 1 are found in the liver [6] where it is
hormonally regulated in a sex- [20,21] and development-de-
pendent [17,22] manner. Oestradiol treatment reduces 11b-
HSD 1 mRNA expression in the liver [20,23], partly explaining
the sexual dimorphism of 11b-HSD 1 expression in the rat
(higher levels in male liver). This effect is thought to be mediated
by the sex-specific secretion of growth hormone [21]. There is
evidence that 11b-HSD 1 expression in liver is up-regulated by
glucocorticoids [24,25], suggesting that glucocorticoids may
modulate their own metabolism, while insulin has been shown to
reduce 11b-HSD 1 expression in hepatocytes and fibroblasts
[25,26].
Abbreviations used: 11b-HSD 1, 11b-hydroxysteroid dehydrogenase type 1; A, 11-dehydrocorticosterone; B, corticosterone; E, cortisone; F, cortisol ;
DTT, dithiothreitol ; IGF 1, insulin-like growth factor 1.
* To whom correspondence should be addressed.
cultured rat liver cell line. In intact 2S FAZA cells 11b-HSD 1
acts predominantly as a reductase, with very low dehydrogenase
activity. In 2S FAZA cells 11b-HSD 1 activity and mRNA
expression are regulated by hormones, with dexamethasone
increasing activity and insulin, forskolin and insulin-like growth
factor 1 decreasing it. Transfection of 2S FAZA cells with a
luciferase reporter gene driven by the proximal promoter of the
rat 11b-HSD 1 gene demonstrates that sequences which can
mediate the responses to insulin, dexamethasone and forskolin
all lie within 1800 bp of the transcription start site.
The liver plays a key role in the regulation of blood glucose
homoeostasis via gluconeogenesis, glycogenolysis and glycogen
synthesis [27]. Glucocorticoids are a major regulator of hepatic
glucose metabolism [28], acting through glucocorticoid receptors,
and 11b-HSD 1 has been suggested to modulate ligand access to
these receptors [29–31]. Evidence is emerging that, in intact
dividing cells and primary cultures of hepatocytes, 11b-HSD 1
acts predominantly as an 11b-reductase [25,32], regenerating
active glucocorticoids from their 11-keto metabolites. Indeed,
studies in humans have shown that inhibition of 11b-HSD
increases insulin sensitivity [33], an effect thought to be mediated
through the liver, presumably by attenuating intrahepatic gluco-
corticoid regeneration by 11b-reductase.
As yet, there are few good models for the study of the
regulation of hepatic 11b-HSD 1, due to the lack of liver-derived
cell lines which express 11b-HSD 1 activity or mRNA. Primary
hepatocyte cultures, while useful, are limited in the extent to
which they can be standardized and manipulated. We have
examined a glucocorticoid- [34] and insulin-sensitive [35] rat
hepatoma cell line (2S FAZA) which expresses important differ-
entiated hepatic functions [36,37]. We have demonstrated 11b-
HSD 1 expression in 2S FAZA cells and shown that it is
hormonally regulated in a similar manner to 11b-HSD 1 in
primary hepatocytes. Transfection experiments show that gluco-
corticoids, insulin and cAMP analogues act on the 11b-HSD 1
promoter within 1800 bp of the transcription start site.
MATERIALS AND METHODS
Materials
Cell culture reagents were obtained from Gibco BRL (Paisley,
Renfrewshire, U.K.). [$H]B was obtained from Amersham In-
ternational (Amersham, Bucks., U.K.). [$H]A was prepared as
described [4]. Briefly, placental extract was incubated in 12 nM
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[$H]B and 1 mM NAD. [$H]A was extracted with ethyl acetate,
dried down under air and resuspended in ethanol. The purity of
preparation was assessed by HPLC and was more than 95%
pure. RNA isolation kits were obtained from Qiagen Ltd,
(Dorking, Surrey, U.K.). The RNase protection assay kit was
obtained from Ambion Inc. (AMS Biotechnology, Witney, Oxon,
U.K.). Luciferin was purchased from Promega, (Southampton).
2S FAZA cells were the kind gift of Dr. Ann Burchell, Ninewells
Hospital and Medical School, Dundee, U.K.
Cells and cell culture
2S FAZA cells were maintained in McCoy’s 5A medium supple-
mented with 10% (v}v) fetal-calf serum, 100 IU}ml penicillin,
100 lg}ml streptomycin and 200 mM l-glutamine. Cells were
transferred into medium containing charcoal-stripped serum
(prepared as described previously [25]) 24 h prior to hormone
addition.
11b-HSD assays
Cells were plated at a density of 2¬10'}60-mm-diam. plate.
Upon reaching confluence hormones were added to the medium.
B or A (25 nM) (consisting of 23 nM unlabelled steroid together
with 2 nM [$H]steroid) was added 24 h after the addition of
hormones. Generally, 200 ll aliquots of medium were taken 6 h
after the addition of corticosteroid, and the [$H]steroid extracted
as described previously [21]. 11b-HSD activity is expressed as the
percentage conversion of substrate into product. Each treatment
in each experiment was carried out on triplicate plates.
RNA preparation
Cells were washed with PBS and then scraped in 150 ll of PBS.
The cells from each triplicate set of plates were pooled and the
total RNA prepared using an RNeasy kit according to the
manufacturer’s instructions.
RNase protection assays
A [$#P]UTP-labelled, 125-base antisense b-actin cRNA was made
by transcription using the pTRI-b-Actin-125 plasmid (supplied
with the RPA II kit from Ambion) and T3 RNA polymerase. A
[$#P]UTP-labelled, 579 bp 11b-HSD 1 antisense cRNA was made
by transcription using T3 RNA polymerase with pBluescript
SKII containing the rat 11b-HSD 1 cDNA (described in [19])
linearized at a StyI site 579 bases from the 3« end.
RNase protection was carried out using the RPA II kit
supplied by Ambion. RNA (10 lg) was mixed with 2¬10' c.p.m.
of 11b-HSD 1 cRNA and 1¬10' c.p.m. of b-actin cRNA,
precipitated, resuspended in 20 ll of hybridization buffer
(Ambion) and hybridized by incubation at 45 °C overnight. The
mixture was treated with 33000 units}ml RNase A and
10000 units}ml RNase T1 for 1 h at 37 °C. The products were
precipitated and separated on a 6% polyacrylamide gel con-
taining 8 M urea. The gel was dried and the protected cRNA
detected by autoradiography. Absorbance of the auto-
radiographs was determined using a computer-driven image
analysis system (Seescan, Cambridge). Film exposure was
adjusted to ensure signal was in the linear range.
Transfections and assay of luciferase activity
The plasmids used were: pSV0L, a promoterless luciferase
reporter gene [38] ; pSV2L, a luciferase reporter gene driven by
the simian virus 40 promoter [38] ; and 11b1-(®1800}­47)-luc,
a luciferase construct containing a HindIII}PstI fragment of the
rat 11b-HSD 1 gene (®1800 to ­47 relative to the major
transcription start site) which was derived from clone kA
described in [16] joined to the PstI}HindIII region of the pUC 18
polylinker and inserted into the HindIII site in pSV0L.
Cells were plated at 5¬10& per 60-mm-diam. plate. After 24 h
cells were transferred into Dulbecco’s modification of Eagle’s
medium supplemented with 10% (v}v) fetal-calf serum, 100 IU
penicillin, 100 units of streptomycin and 200 mM l-glutamine.
After 1 h, cells were transfected with 10 lg of plasmid DNA
(5 lg of test plasmid, 5 lg of pGEM-3) using the calcium
phosphate procedure [39]. The transfection medium}DNA pre-
cipitate was removed 24 h later and replaced with 2S FAZA
medium with the specified hormones added. After a further 24 h,
the cells were washed with PBS and then lysed by the addition of
150 ll of lysis buffer [25 mM Tris phosphate, pH 7.8, 2 mM
dithiothreitol (DTT), 1% Triton X-100, 10% (v}v) glycerol].
The lysed cells were scraped, centrifuged briefly and the luciferase
activity in the supernatant determined using a Berthold lumino-
meter. Luciferase activity was assayed in a mixture containing
40 ll of cell extract, 5 ll of 5 mM ATP, 100 ll of assay buffer
[20 mM tricine, 1.07 nM (MgCO
$
)
%
.Mg(OH)
#
,5H
#
O, 2.6 mM
MgSO
%
, 0.1 mM EDTA, 33.3 mM DTT, 0.2 mg}ml coenzyme
A]. Assays were initiated by the injection of 105 ll of 1 mM
luciferin. Light emission was measured over 10 s and relative
light units (RLU)}lg of protein were calculated. In all experi-
ments, treatments were carried out on triplicate plates.
Statistics
Data were analysed using ANOVA followed by the Dunnett
multiple comparisons test or Fisher PLSD (probability of least
squares difference) test. Significance was set at P! 0.05. Values
are mean³S.E.M.
RESULTS
11b-HSD activity and expression in 2S FAZA cells
Assay of 11b-HSD in intact 2S FAZA cells showed pre-
dominantly 11b-reductase activity converting A added to the
medium to B (21³4% after 4 h, 58³4% after 24 h). De-
hydrogenase activity was detectable only after 24 h incubation
(15³4% conversion of B into A). The presence of mRNA
encoding 11b-HSD 1 was confirmed by RNase protection analy-
sis (for example see Figure 1A) and by reverse-transcription PCR
(results not shown).
Hormonal regulation of 11b-HSD in 2S FAZA cells
11b-HSD 1 enzyme activity and mRNA were measured in 2S
FAZA cells treated for 24 h with 10 nM dexamethasone,
20 lg}ml insulin, 20 ng}ml insulin-like growth factor 1 (IGF 1),
10 lM forskolin or a combination of hormones, after which 11b-
reductase activity was measured by the conversion of [$H]A to
[$H]B in the medium over a period of 6 h (Table 1). Following
11b-HSD assay, cells were harvested and RNA encoding 11b-
HSD 1 assayed by RNase protection analysis. Treatment with
10 nM dexamethasone led to a significant increase in 11b-
reductase activity while 20 ng}ml IGF 1, 20 lg}ml insulin and
10 lM forskolin treatment all reduced 11b-reductase activity to
a similar degree. The effects of adding IGF 1 together with either
insulin or forskolin were similar to the individual treatments and
were not additive. When dexamethasone was added in com-
bination with either IGF 1, insulin or forskolin, then the effect of
dexamethasone was dominant.
Measurement of 11b-HSD 1 mRNA levels by RNase pro-
tection analysis demonstrated that 11b-HSD 1 mRNA levels
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Figure 1 RNase protection analysis of 11b-HSD 1 mRNA levels in hormone-
treated 2S FAZA cells
(A) Autoradiograph of RNase protection analysis of total RNA from hormone-treated 2S FAZA
cells. Hormone treatment was as described for Table 1. A 10 lg sample of total RNA was
hybridized with 1¬106 c.p.m. of actin and 2¬106 c.p.m. of 11b-HSD 1 radiolabelled cRNAs
at 45 °C overnight. The autoradiograph was exposed for 2 h for the actin and 48 h for the 11b-
HSD bands. The data are representative of three independent experiments. (B) Quantification
of RNase protection assays carried out as described in (A) and expressed as the ratio between
11b-HSD 1 and actin. Data are expressed as a percentage of the control (untreated) level. The
values are the mean³S.E.M. derived from data from three independent experiments.
Abbreviations : Ins, insulin ; IGF, IGF 1 ; Dex, dexamethasone ; For, forskolin. *P ! 0.05,
compared with control.
were significantly decreased by treatment of cells with insulin,
while forskolin tended to reduce mRNA levels, but this did not
achieve statistical significance (Figure 1). Neither IGF 1 nor
dexamethasone treatment appreciably altered the level of 11b-
HSD 1 mRNA, but dexamethasone in conjunction with insulin
increased the level of 11b-HSD 1 mRNA.
To determine whether insulin was acting on 11b-HSD 1
through the IGF 1 receptor, a concentration response to insulin
was determined (Figure 2). The concentration of insulin for half-
maximal effect was between 10−* and 10−"! M, similar to the
normal physiological concentration of insulin in plasma and the
K
d
of the insulin receptor [40].
Hormonal responsiveness in 2S FAZA cells is conferred by the
proximal promoter of the rat 11b-HSD 1 gene
Transfection into 2S FAZA cells of a plasmid bearing a HindIII-
PstI fragment of the rat 11b-HSD 1 proximal promoter (®1800
Table 1 Effect of hormone treatments on 11b-HSD 1 enzyme activity in 2S
FAZA cells in culture
Twenty-four hours prior to the addition of hormone, cells were plated in medium containing
serum stripped of steroids and endogenous small peptides. Hormones used were dexamethasone
(10 nM), insulin (20 lg/ml), IGF 1 (20 ng/ml) and forskolin (10 lM) either singly or in
combination. Following the addition of hormone for 24 h, 11b-HSD activity in 2S FAZA cells
was assayed by the conversion of [3H]A added to the medium over a 6 h period. Activity is
expressed as percentage of control³S.E.M. Conversion by control cells was 16.4³0.4%.
Each value represents the mean of triplicate plates. The data are representative of three
independent experiments. *P ! 0.05, compared with control.
Treatment 11b-HSD 1 activity (% of Control)
Control 100³2
20 lg/ml (3.5 M) Insulin 51³2*
10 nM Dexamethasone 192³9*
20 ng/ml IGF 1 65³2*
10 lM Forskolin 66³7*
Insulin­dexamethasone 291³4*
IGF 1­dexamethasone 221³4*
Forskolin­dexamethasone 142³3*
Insulin­IGF 1 55³4*
Insulin­forskolin 75³7*
IGF 1­forskolin 72³7*
Figure 2 Concentration–response curve of 11b-HSD 1 activity with chang-
ing insulin concentration
For 24 h prior to the addition of insulin, cells were plated in medium containing serum stripped
of steroids and endogenous small peptides. Following the addition of insulin for 24 h, 11b-HSD
activity in 2S FAZA cells was assayed by the conversion of [3H]A to [3H]B in the medium over
a 6 h period. Activity is expressed as percentage conversion³S.E.M. of [3H]A to [3H]B. Each
value represents the mean of triplicate plates. The data are representative of three independent
experiments. *P ! 0.01, compared with 3¬10−12 M.
to ­47) fused to a luciferase reporter gene demonstrated that
this region contained hormone-responsive elements (Figure 3).
Dexamethasone treatment of 2S FAZA cells transfected with
p11b-1(®1800}­47)-luc led to significantly increased luciferase
activity, whereas it had no effect on luciferase activity directed by
the control plasmids pSV0L or pSV2L. Both forskolin and
insulin treatment of 2S FAZA cells transfected with p11b-
1(®1800}­47)-luc lowered luciferase activity in relation to cells
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Figure 3 Effect of hormone treatments on transcription from the 11b-
HSD 1 gene promoter
2S FAZA cells were transfected with p11b1-(®1800/­47)-luc (a luciferase reporter gene
driven by the proximal promoter of 11b-HSD 1), pSV0L (a promoterless luciferase reporter
gene) or pSV2L (a luciferase reporter gene driven by the SV40 promoter). Twenty-four hours
after transfection, hormone was added and incubation continued for a further 24 h before
harvesting for assay of luciferase activity. Results are expressed as the ratio of luciferase activity
(RLU/lg of protein) in the absence of hormone to luciferase activity in the presence of hormone
(fold induction³S.E.M.). Typically, basal luciferase activity was 2.2 relative light units
(RLU)/lg of protein for pSV0L, 850 RLU/lg of protein for pSV2L and 42 RLU/lg of protein
for p11b-1(®1800/­47)-luc. All transfections were performed in triplicate, data are the
means of at least three independent experiments. *P ! 0.05 compared with pSV2L and pSV0L.
transfected with the control plasmids. Insulin treatment caused a
slight increase in luciferase expression in cells transfected with
the control plasmids, probably due to its general growth-
stimulating effects at this concentration. IGF 1 had no significant
effect on luciferase activity in cells transfected with any of the
reporter plasmids.
DISCUSSION
Assay of 11b-HSD in growing 2S FAZA cells demonstrated that
they expressed 11b-reductase activity with negligible dehydro-
genase activity, and RNase protection analysis confirmed the
presence of 11b-HSD 1 mRNA. This supports recent data
showing that in intact cells transfected with 11b-HSD 1 ex-
pression vectors and in primary hepatocytes in culture, 11b-
HSD 1 acts as a reductase [25,32]. In all three systems, the
dehydrogenase activity of 11b-HSD 1 is very low, suggesting
that, in io, the primary function of 11b-HSD 1 in hepatocytes
is the regeneration of active glucocorticoids. This is in agreement
with some in io data [41,42].
11b-HSD 1 activity is hormonally regulated in 2S FAZA cells
and reflects the regulation seen in the liver in io and in primary
cultures of hepatocytes [24,25]. In both primary hepatocytes and
2S FAZA cells short-term dexamethasone treatment increases,
and insulin decreases, expression of 11b-HSD 1, with the effect
of dexamethasone being dominant within physiologically mean-
ingful concentrations. The length of hormone treatment differs
between the studies, but all are short term and regulation of 11b-
HSD 1 in 2S FAZA cells is similar to that in the liver and
primary hepatocyte cultures. Forskolin and IGF 1 treatment
both reduce 11b-HSD 1 activity in 2S FAZA cells. Forskolin
reduces 11b-HSD 1 mRNA levels in 2S FAZA cells, but IGF 1
does not affect the 11b-HSD 1 mRNA levels, suggesting that it
may act post-transcriptionally. The action of forskolin suggests
that hormones which act by altering intracellular cAMP levels,
such as glucagon, may be involved in the regulation of 11b-
HSD 1. As cell lines are much more amenable to manipulation
than primary hepatocyte cultures they are the preferred system
with which to investigate the molecular mechanisms involved in
11b-HSD 1 expression.
Preliminary studies in which 2S FAZA cells were transfected
with 11b1-(®1800}­47)-luc show that dexamethasone, insulin
and forskolin may act directly on transcription with dexa-
methasone increasing, and forskolin and insulin decreasing,
transcription of the 11b-HSD 1 gene. The transfections also
showed that sensitivity to dexamethasone, insulin and forskolin
is conferred by sites within the proximal 1800 bases of 5« flanking
DNA of the 11b-HSD 1 gene. This region contains a number of
protein-binding sites, several of which correspond to sites for the
liver-enriched transcription factor, C}EBP, and which are pro-
tected by proteins in rat liver nuclear extracts from digestion by
DNase 1 [43]. 2S FAZA cells, therefore, represent an ideal
system for the further analysis of the 11b-HSD 1 promoter
region.
In the rat, levels of A are around 50–100 nM (R. Best and J.
R. Seckl, unpublished work). As A is largely unbound in the
circulation and can freely cross the cell membrane, the liver has
the potential to produce high intracellular levels of active B from
A via 11b-HSD 1. Moreover, for most of the day, ‘ free ’ B levels
are considerably lower than A (similarly E levels are higher than
‘free ’ F in humans [42]). Thus A has considerably greater
potential to influence intracellular B levels (via 11b- HSD 1) and
thus glucocorticoid receptor activity, than circulating B itself for
most of the day. The key pathways involved in the regulation of
blood glucose by the liver are regulated by glucocorticoids
together with insulin and glucagon [28]. Glucocorticoids increase
the insulin activation of glucokinase [44] and are a permissive
requirement for pyruvate kinase activity [28], both of which are
enzymes involved in glycolysis. In the absence of other hormones,
however, the overall action of glucocorticoids in the liver is to
promote hepatic glucose output via gluconeogenesis, stimulating
the expression of glucose-6-phosphatase, fructose-1,6-bisphos-
phatase and phosphoenolpyruvate carboxykinase [28,34], and
to increase glucose storage in the liver via glycogen synthase
[45]. Clearly then, the presence of hormonally regulated 11b-
HSD 1 in the liver may add a further level of control of hepatic
glucose output by determining the intracellular levels of active
glucocorticoid. In addition, inappropriate 11b-HSD 1 ampli-
fication of glucocorticoid action may attenuate insulin sensitivity,
leading to hepatic insulin resistance, hyperglycaemia and diabetes
mellitus.
This cell line, expressing endogenous 11b-HSD 1, provides an
excellent, easily manipulated model in which to investigate the
molecular mechanisms involved in the regulation of 11b-HSD 1
and its role in determining the glucocorticoid sensitivity of
hepatic function.
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